N. Galiè, M. Humbert, J. Vachiery, S. Gibbs, I. Lang et al., , 2015.

. Esc/ers, Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur Heart J, vol.37, issue.1, pp.67-119, 2016.

L. A. Shimoda and S. S. Laurie, Vascular remodeling in pulmonary hypertension, J Mol Med, vol.91, issue.3, 2013.

Y. Alkhatib, D. Albashaireh, T. Al-aqtash, A. , and R. , The role of tyrosine kinase inhibitor "Lapatinib" in pulmonary hypertension, Pulm. Pharmacol. Ther, vol.37, pp.81-84, 2016.

A. Andruska, S. Dannewitz, D. Sudheendra, X. Tian, M. Nagendran et al., Lymphocyte Specific Protein Tyrosine Kinase (LCK), a Novel BMPR2, 2017.

. Modulator, Situ Transcriptome Profiling

K. S. Awad, J. M. Elinoff, S. Wang, S. Gairhe, G. A. Ferreyra et al., Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells, Am. J. Physiol. -Lung Cell. Mol. Physiol, vol.310, pp.187-201, 2016.

B. Baumgart, M. Guha, J. Hennan, J. Li, J. Woicke et al., In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension, Cancer Chemother. Pharmacol, vol.79, pp.711-723, 2017.

E. Berghausen, H. Ten-freyhaus, and S. Rosenkranz, Targeting of Platelet-Derived Growth Factor Signaling in Pulmonary Arterial Hypertension, Pharmacotherapy of Pulmonary Hypertension, pp.381-408, 2013.

D. H. Best, K. L. Sumner, B. P. Smith, K. Damjanovich-colmenares, I. Nakayama et al., EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension, Chest, vol.151, pp.821-828, 2017.

O. Boucherat, G. Vitry, I. Trinh, R. Paulin, S. Provencher et al., The cancer theory of pulmonary arterial hypertension, Pulm. Circ, vol.7, pp.285-299, 2017.

P. Cai, L. Kovacs, S. Dong, G. Wu, and Y. Su, BMP4 inhibits PDGF-induced proliferation and collagen synthesis via PKA-mediated inhibition of calpain-2 in pulmonary artery smooth muscle cells, Am. J. Physiol. -Lung Cell. Mol. Physiol, vol.312, pp.638-648, 2017.

A. Chida, M. Shintani, T. Nakayama, Y. Furutani, E. Hayama et al., Missense mutations of the BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension, Circ. J. Off. J. Jpn. Circ. Soc, vol.76, pp.1501-1508, 2012.

A. C. Church, D. H. Martin, R. Wadsworth, G. Bryson, A. J. Fisher et al., The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension, Am. J. Physiol.-Lung Cell. Mol. Physiol, vol.309, pp.333-347, 2015.

A. Cortelezzi, G. Gritti, N. Del-papa, M. C. Pasquini, R. Calori et al., Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status, Leukemia, vol.22, pp.646-649, 2008.
DOI : 10.1038/sj.leu.2404943

URL : https://www.nature.com/articles/2404943.pdf

B. K. Dahal, T. Cornitescu, A. Tretyn, S. S. Pullamsetti, D. Kosanovic et al., Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension, Am. J. Respir. Crit. Care Med, vol.181, pp.158-167, 2010.

M. Das, M. Zawada, J. West, and K. Stenmark, JNK2 Regulates Vascular Remodeling in Pulmonary Hypertension, 2016.
DOI : 10.1177/2045894018778156

URL : https://doi.org/10.1177/2045894018778156

E. C. Derrett-smith, A. Dooley, A. J. Gilbane, S. L. Trinder, K. Khan et al., Endothelial Injury in a Transforming Growth Factor ?-Dependent Mouse Model of Scleroderma Induces Pulmonary Arterial Hypertension: PAH in a Mouse Model of Scleroderma, Arthritis Rheum, vol.65, pp.2928-2939, 2013.

L. Dewachter, C. Dewatcher, A. Belhaj, S. Lalande, B. Rondelet et al., Insulin-like growth factor-1 contributes to the pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension, Eur. Respir. J, vol.44, p.316, 2014.

C. A. Eichstaedt, J. Song, N. Benjamin, S. Harutyunova, C. Fischer et al., EIF2AK4 mutation as "second hit" in hereditary pulmonary arterial hypertension, Respir. Res, 2016.

S. Farha, R. Dweik, F. Rahaghi, R. Benza, P. Hassoun et al., Imatinib in Pulmonary Arterial Hypertension: C-Kit Inhibition, Pulm. Circ, vol.4, pp.452-455, 2014.
DOI : 10.1086/677359

URL : http://journals.sagepub.com/doi/pdf/10.1086/677359

A. E. Frost, R. J. Barst, M. M. Hoeper, H. Chang, R. P. Frantz et al., Long-term safety and efficacy of imatinib in pulmonary arterial hypertension, J. Heart Lung Transplant, vol.34, pp.1366-1375, 2015.

N. Galiè, M. Humbert, J. Vachiery, S. Gibbs, I. Lang et al., 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur. Heart J, vol.37, pp.67-119, 2016.

B. Girerd, J. Weatherald, D. Montani, H. , and M. , Heritable pulmonary hypertension: from bench to bedside, Eur. Respir. Rev, vol.26, p.170037, 2017.
DOI : 10.1183/16000617.0037-2017

URL : http://err.ersjournals.com/content/errev/26/145/170037.full.pdf

B. Gore, M. Izikki, O. Mercier, L. Dewachter, E. Fadel et al., Key Role of the Endothelial TGF-?/ALK1/Endoglin Signaling Pathway in Humans and Rodents Pulmonary Hypertension, PLoS ONE, vol.9, 2014.

M. R. Green, M. D. Newton, and K. M. Fancher, Off-Target Effects of BCR-ABL and JAK2 Inhibitors: Am, J. Clin. Oncol, vol.39, pp.76-84, 2016.

C. Guignabert, C. Phan, A. Seferian, A. Huertas, L. Tu et al., Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension, J. Clin. Invest, vol.126, pp.3207-3218, 2016.

P. Guilpain, D. Montani, G. Damaj, L. Achouh, F. Lefrère et al., Pulmonary Hypertension Associated with Myeloproliferative Disorders: A Retrospective Study of Ten Cases, Respiration, vol.76, pp.295-302, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00356272

M. M. Hoeper, V. V. Mclaughlin, A. M. Dalaan, T. Satoh, and N. Galiè, Treatment of pulmonary hypertension, Lancet Respir. Med, vol.4, pp.323-336, 2016.

R. K. Hopper, J. A. Feinstein, M. A. Manning, W. Benitz, and L. Hudgins, Neonatal pulmonary arterial hypertension and Noonan syndrome: Two fatal cases with a specific RAF1 mutation, Am. J. Med. Genet. A, vol.167, pp.882-885, 2015.

M. Humbert, Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology, Eur. Respir. Rev, vol.19, pp.59-63, 2010.

C. Hwangbo, H. Lee, H. Kang, H. Ju, D. S. Wiley et al., Modulation of Endothelial Bone Morphogenetic Protein Receptor Type, 2017.

, Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial HypertensionClinical Perspective, Circulation, vol.135, pp.2288-2298

J. C. Ibe, Q. Zhou, T. Chen, H. Tang, J. X. Yuan et al., Adenosine Monophosphate-Activated Protein Kinase Is Required for Pulmonary Artery Smooth Muscle Cell Survival and the Development of Hypoxic Pulmonary Hypertension, Am. J. Respir. Cell Mol. Biol, vol.49, pp.609-618, 2013.

M. Izikki, C. Guignabert, E. Fadel, M. Humbert, L. Tu et al., Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents, J. Clin. Invest, vol.119, pp.512-523, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00499635

J. Kim, Apelin-APJ Signaling: a Potential Therapeutic Target for Pulmonary Arterial Hypertension, Mol. Cells, vol.37, pp.196-201, 2014.
DOI : 10.14348/molcells.2014.2308

URL : http://www.molcells.org/journal/download_pdf.php?doi=10.14348/molcells.2014.2308

G. Kimura, M. Kataoka, T. Inami, K. Fukuda, H. Yoshino et al., Sorafenib as a potential strategy for refractory pulmonary arterial hypertension, Pulm. Pharmacol. Ther, vol.44, pp.46-49, 2017.

M. J. Lachmann, S. Yuasa, and K. Fukuda, 5024JAK1/2 inhibitor ruxolitinib restores the responsiveness to hypoxia in pulmonary arterial hypertension-iPSC-derived endothelial cells, Eur. Heart J, vol.38, 2017.

E. M. Lau, E. Giannoulatou, D. S. Celermajer, H. , and M. , Epidemiology and treatment of pulmonary arterial hypertension, Nat. Rev. Cardiol, vol.14, pp.603-614, 2017.

H. De-lavallade, S. Punnialingam, D. Milojkovic, M. Bua, J. S. Khorashad et al., Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis, Br. J. Haematol, vol.141, pp.745-747, 2008.

A. T. Low, L. Howard, C. Harrison, and R. M. Tulloh, Pulmonary arterial hypertension exacerbated by ruxolitinib, Haematologica, vol.100, pp.244-245, 2015.
DOI : 10.3324/haematol.2014.120816

URL : http://www.haematologica.org/content/100/6/e244.full.pdf

M. M. Mattar, M. A. Morad, N. M. El-husseiny, N. H. Ali, and D. M. Demerdash, Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience, Ann. Hematol, vol.95, pp.1611-1616, 2016.

D. Mattei, M. Feola, F. Orzan, N. Mordini, D. Rapezzi et al., Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient, Bone Marrow Transplant, vol.43, pp.967-968, 2009.

M. Minami, T. Arita, H. Iwasaki, T. Muta, T. Aoki et al., Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib, Br. J. Haematol, vol.177, pp.578-587, 2017.

N. I. Moguillansky, H. A. Fakih, and J. R. Wingard, Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity, Respir. Med. Case Rep, vol.21, pp.154-157, 2017.

D. Montani, M. Chaumais, C. Guignabert, S. Günther, B. Girerd et al., Targeted therapies in pulmonary arterial hypertension, Pharmacol. Ther, vol.141, pp.172-191, 2014.

H. Mucke, The role of imatinib in the treatment of pulmonary hypertension, Drugs Today Barc. Spain, vol.49, pp.203-211, 1998.

M. R. Nicolls, S. Mizuno, L. Taraseviciene-stewart, L. Farkas, J. I. Drake et al., New Models of Pulmonary Hypertension Based on VEGF Receptor Blockade-Induced Endothelial Cell Apoptosis, Pulm. Circ, vol.2, pp.434-442, 2012.

J. Omura, K. Satoh, N. Kikuchi, T. Satoh, R. Kurosawa et al., Protective Roles of Endothelial AMP-Activated Protein Kinase Against Hypoxia-Induced Pulmonary Hypertension in MiceNovelty and Significance, Circ. Res, vol.119, pp.197-209, 2016.

D. Patel, R. Alhawaj, and M. S. Wolin, Exposure of mice to chronic hypoxia attenuates pulmonary arterial contractile responses to acute hypoxia by increases in extracellular hydrogen peroxide, Am. J. Physiol.-Regul. Integr. Comp. Physiol, vol.307, pp.426-433, 2014.

R. Paulin, J. Meloche, A. Courboulin, C. Lambert, A. Haromy et al., Targeting cell motility in pulmonary arterial hypertension, Eur. Respir. J, vol.43, pp.531-544, 2014.

E. Poluzzi, E. Raschi, C. Piccinni, and F. De, Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS), Data Mining Applications in Engineering and Medicine, A. Karahoca, 2012.

K. W. Prins and T. Thenappan, World Health Organization Group I Pulmonary Hypertension, Cardiol. Clin, vol.34, pp.363-374, 2016.
DOI : 10.1016/j.ccl.2016.04.001

URL : http://europepmc.org/articles/pmc4959804?pdf=render

S. S. Pullamsetti, E. M. Berghausen, S. Dabral, A. Tretyn, E. Butrous et al., Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension, Arterioscler. Thromb. Vasc. Biol, vol.32, pp.1354-1365, 2012.

S. S. Pullamsetti, E. M. Berghausen, S. Dabral, A. Tretyn, E. Butrous et al., Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension, Arterioscler. Thromb. Vasc. Biol, vol.32, pp.1354-1365, 2012.

A. Quintás-cardama, H. Kantarjian, S. O'brien, G. Borthakur, J. Bruzzi et al.,

, Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure, J. Clin. Oncol, vol.25, pp.3908-3914

R. Rix, L. L. Rix, U. Colinge, J. Hantschel, O. Bennett et al., Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells, Leukemia, vol.23, pp.477-485, 2009.

K. Sada, T. Nishikawa, D. Kukidome, T. Yoshinaga, N. Kajihara et al., Hyperglycemia Induces Cellular Hypoxia through Production of Mitochondrial ROS Followed by Suppression of Aquaporin-1, PLOS ONE, vol.11, p.158619, 2016.

O. Sakamoto, M. Suga, T. Suda, A. , and M. , Expression of discoidin domain receptor 1 tyrosine kinase on the human bronchial epithelium, Eur. Respir. J, vol.17, pp.969-974, 2001.

C. Sawyers, Targeted cancer therapy, Nature, vol.432, pp.294-297, 2004.

R. T. Schermuly, Reversal of experimental pulmonary hypertension by PDGF inhibition, J. Clin. Invest, vol.115, pp.2811-2821, 2005.

R. T. Schermuly, H. A. Ghofrani, M. R. Wilkins, and F. Grimminger, Mechanisms of disease: pulmonary arterial hypertension, Nat. Rev. Cardiol, vol.8, pp.443-455, 2011.

S. Shapiro, G. L. Traiger, M. Turner, M. D. Mcgoon, P. Wason et al., Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management, Chest, vol.141, pp.363-373, 2012.

T. Shimizu, Y. Fukumoto, S. Tanaka, K. Satoh, S. Ikeda et al., Crucial Role of ROCK2 in Vascular Smooth Muscle Cells for Hypoxia-Induced Pulmonary Hypertension in Mice, Arterioscler. Thromb. Vasc. Biol, vol.33, pp.2780-2791, 2013.

G. P. Star, M. Giovinazzo, and D. Langleben, Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cellsA potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension, Microvasc. Res, vol.80, pp.349-354, 2010.

M. Sun, R. Ramchandran, J. Chen, Q. Yang, R. et al., Smooth Muscle Insulin-Like Growth Factor-1 Mediates Hypoxia-Induced Pulmonary Hypertension in Neonatal Mice, Am. J. Respir. Cell Mol. Biol, vol.55, pp.779-791, 2016.

J. Tenorio, P. Navas, E. Barrios, L. Fernández, J. Nevado et al., A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies: EIF2AK4 mutation causing pulmonary arterial hypertension in Iberian Gypsies, Clin. Genet, vol.88, pp.579-583, 2015.

T. Thenappan, M. L. Ormiston, J. J. Ryan, and S. L. Archer, Pulmonary arterial hypertension: pathogenesis and clinical management, BMJ j5492, 2018.
DOI : 10.1136/bmj.j5492

N. F. Tojais, A. Cao, Y. Lai, L. Wang, P. Chen et al., Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-? in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial HypertensionHighlights, Arterioscler. Thromb. Vasc. Biol, vol.37, pp.1559-1569, 2017.

P. D. Upton and N. W. Morrell, The transforming growth factor-?-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease: Signalling pathways in pulmonary vasculature, Exp. Physiol, vol.98, pp.1262-1266, 2013.

B. Vaidya, M. Pangallo, G. Ruffenach, C. M. Cunningham, J. C. Perron et al., Advances in treatment of pulmonary arterial hypertension: patent review, Expert Opin. Ther. Pat, vol.27, pp.907-918, 2017.

J. Weatherald, M. Chaumais, and D. Montani, Pulmonary arterial hypertension induced by tyrosine kinase inhibitors, Curr. Opin. Pulm. Med, vol.1, 2017.
DOI : 10.1097/mcp.0000000000000412

J. L. Wilson, J. Yu, L. Taylor, and P. Polgar, Hyperplastic Growth of Pulmonary Artery Smooth Muscle Cells from Subjects with Pulmonary Arterial Hypertension Is Activated through JNK and p38 MAPK, PLOS ONE, vol.10, p.123662, 2015.

Y. Zheng, H. Ma, E. Hu, Z. Huang, X. Cheng et al., Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression, J. Cardiovasc. Pharmacol, vol.66, pp.504-514, 2015.